1910 Genetics, a Boston, MA-based biotechnology firm advancing small and enormous molecule drug discovery with a multimodal AI platform empowered by laboratory automation, obtained an funding from Accenture Ventures.
The quantity of the deal was not disclosed.
The corporate intends to make use of the funds to increase operations and its growth efforts.
Based by CEO Jen Nwankwo, 1910 Genetics is a small and enormous molecule drug discovery firm offering multimodal AI platform empowered by laboratory automation. It integrates AI that leverages federated studying alongside three proprietary information streams to ship novel drug candidates and software program options to biopharma and tech companions, and advance its inner pipeline for neurological, autoimmune ailments, and most cancers. It just lately established a industrial partnership with Microsoft to carry our ITO™ platform to biopharma corporations at scale.
Along with this announcement, Dr. Petra Jantzer and Tom Lounibos will be part of the Enterprise Advisory Board of 1910, and Dr. Kailash Swarna, a managing director in Life Sciences at Accenture, and Dr. Cecil Lynch, Biomedical Informatics lead at Accenture, will be part of the Expertise Advisory Board of 1910.
As a part of this funding, Accenture and 1910 will collaborate to mix tailor-made options and scalable infrastructure to assist purchasers within the biopharma trade speed up drug goal identification, scale back prices, and ship higher, extra reasonably priced therapies to sufferers.
1910 was launched in 2021 with a mixed seed and Collection A funding of $26.1M from M12-Microsoft’s Enterprise Fund, Playground International, OpenAI’s Sam Altman, FoundersX Ventures, and different traders.
FinSMEs
31/10/2024
